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Inositol levels, maintained by the biosynthetic enzyme inositol-3-phosphate synthase (Ino1), are altered in a range of disorders,
including bipolar disorder and Alzheimer’s disease. To date, most inositol studies have focused on the molecular and cellular
effects of inositol depletion without considering Ino1 levels. Here we employ a simple eukaryote, Dictyostelium discoideum, to
demonstrate distinct effects of loss of Ino1 and inositol depletion. We show that loss of Ino1 results in an inositol auxotrophy
that can be rescued only partially by exogenous inositol. Removal of inositol supplementation from the ino1mutant resulted in
a rapid 56% reduction in inositol levels, triggering the induction of autophagy, reduced cytokinesis, and substrate adhesion. Ino-
sitol depletion also caused a dramatic generalized decrease in phosphoinositide levels that was rescued by inositol supplementa-
tion. However, loss of Ino1 triggered broad metabolic changes consistent with the induction of a catabolic state that was not res-
cued by inositol supplementation. These data suggest a metabolic role for Ino1 that is independent of inositol biosynthesis. To
characterize this role, an Ino1 binding partner containing SEL1L1 domains (Q54IX5) and having homology to mammalian mac-
romolecular complex adaptor proteins was identified. Our findings therefore identify a new role for Ino1, independent of inosi-
tol biosynthesis, with broad effects on cell metabolism.
A stereoisomer of inositol,myo-inositol, is present in a varietyof cell types and is obtained from the following three major
sources: de novo synthesis from glucose-6-phosphate, sequential
dephosphorylation of phosphoinositides, and membrane trans-
port from extracellular fluid (1). Disruption of inositol homeosta-
sis has been associated with a number of illnesses, including bipo-
lar disorder (2–5), Alzheimer’s disease (6–9), bulimia (10),
metabolic syndrome (11), diabetes (12, 13), and epilepsy (14).
Understanding the cellular and metabolic changes resulting from
inositol depletion will provide insight into the mechanisms un-
derlying these diseases.
Inositol-3-phosphate synthase (Ino1; EC 5.5.1.4) is crucial for
the de novo biosynthesis of inositol, as it is an isomerase that con-
verts glucose-6-phosphate to inositol-3-phosphate, which is then
dephosphorylated to inositol (15) (Fig. 1A). Inositol is an essential
precursor of a large family of phosphoinositides (16), with one of
these, phosphoinositide 4,5 bisphosphate (PIP2), used in the pro-
duction of inositol phosphates. Thesemolecules are important for
a range of cellular functions, including motility (17), activation of
signal transduction pathways (18), membrane trafficking and ve-
sicular transport (1), protein secretion, and transcriptional regu-
lation (19). Despite these broad functions, few studies have com-
pared the physiological effects of reducing inositol levels and
reducing Ino1 levels; therefore, it remains unclear if these two
activities have distinct roles.
Dictyostelium discoideum is a single-celled eukaryote found in
forest soils, where it survives by consuming bacteria.Dictyostelium
is used as a research model in a variety of disciplines, including
biomedicine. We previously employed Dictyostelium in a 3Rs ap-
proach (animal reduction, replacement, and refinement) for bio-
medical research to investigate the effects of epilepsy treatments
on modulating phosphoinositide signaling and seizure control
(14, 20) and the effects of bipolar disorder treatments on the levels
of inositol phosphates (5, 21). These findings were successfully
translated to mammalian disease models (14, 21, 22). Dictyoste-
lium was also used to identify targets for compounds involved in
bitter tastant detection (23, 24) and conserved roles of homo-
logues of human proteins (23, 25) and to investigate mitochon-
drial disease (26), Huntington’s disease (27), and centrosomal or-
ganization and function (28, 29). These studies suggest that
Dictyostelium can inform our understanding of cellular function
relevant to human disease.
Dictyostelium was previously employed to investigate the role
of Ino1 in cell function (30), where insertionalmutagenesis of ino1
produced an inositol-auxotrophic phenotype with a concomitant
decrease in inositol trisphosphate. Here we independently deleted
a key region of the ino1 gene in an isogenic cell line and found that
growth of the ino1 mutant can be rescued only partially by ex-
ogenous inositol, suggesting a nonbiosynthetic role for the pro-
tein. We further show that the previously described “inositol-less
death” is likely to lead to an upregulation of autophagy, loss of
substrate adhesion, and reduced cytokinesis resulting from inosi-
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tol depletion. We also show that inositol depletion leads to a gen-
eralized reduction of phosphoinositide levels, without gross
changes inmetabolic profile. Surprisingly, we show that the great-
est metabolic change is caused by a loss of Ino1, not by inositol
depletion per se, since broadmetabolic changes are not rescued by
exogenous inositol, suggesting distinct effects of Ino1 loss and
inositol depletion on cellular function. Finally, we identified a
range of potential Ino1 binding partners and confirmed direct
Ino1 binding to a protein withmammalian homologues that serve
as adaptors involved in the attachment to macromolecular com-
plexes, providing a potential link to regulating inositol-indepen-
dent cellular functions.
MATERIALS AND METHODS
Materials. Axenic,HL5, andLoFlomediawere purchased fromForMedium
Co. Ltd. (Hunstanton, United Kingdom). All restriction enzymes and first-
strand cDNA synthesis kits were purchased from Fermentas (St. Leon-Rot,
Germany). Tris-HCl, NaCl, EDTA, 4=,6-diamidino-2-phenylindole (DAPI),
FIG 1 Inositol signaling and conservation of the Ino1 protein in Dictyostelium and humans. (A) Inositol metabolism. Ino1 converts glucose-6-phosphate to
inositol-3-phosphate, which is a rate-limiting step in inositol production. (B) Sequence homology between the human (accession no. Q9NPH2-1) and Dictyo-
stelium (accession no. Q54N49) Ino1 proteins is present throughout the protein sequences. Identical amino acids are shown in dark blue. The NAD binding and
catalytic domains are among the four regions that are highly conserved in eukaryotic Ino1 proteins, i.e., for the human protein GWGGNNG (orange),
LWTANTERY (blue), SYNHLGNNDG (green), and NGSPQNTFVPGL (purple). The tetramerization domain, containing a putative catalytic site (with the
conserved amino acid residues SYNHLGNNDG), is shown in red. The amino acids that were ablated inDictyostelium Ino1 are shown by the horizontal line. (C)
Alignment of the conserved regions of Ino1 proteins from various species. Asterisks show identity, colons show high conservation levels, and dots show low
conservation levels. (D) Schematic representation of the strategy used to prepare the ino1 knockout construct. 5= and 3= regions of the ino1 gene were cloned into
a knockout vector at positions flanking the blasticidin resistance gene (bsr), and the knockout cassette was transformed into Dictyostelium cells, where homol-
ogous recombination deleted a portion of the ino1 gene and disrupted the open reading frame. (E) PCR screening strategy to identify ino1mutants, showing
primer locations for genomic and vector controls, the diagnostic knockout products (KO), and the area spanning the inserted bsr gene present in the ino1
knockout. (F) PCR results showing the ablation of part of the ino1 gene in the ino1 mutant in comparison to wild-type cells. Ino1, inositol-3-phosphate
synthase; IMPase, inositol monophosphatase; IPPase, inositol polyphosphate 1-phosphatase; IP2, inositol bisphosphate; IP3, inositol trisphosphate; PLC,
phospholipase C; PI, phosphatidylinositol; PIP, phosphatidylinositol phosphate; PIP2, phosphatidylinositol bisphosphate; PIP3, phosphatidylinositol trispho-
sphate; bsr, blasticidin resistance gene; G, genomic control; V, vector control; KO, knockout; 5=, region corresponding to the transcription initiation site of the
ino1 gene; 3=, region corresponding to the transcription termination site of the ino1 gene.
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cyclic AMP (cAMP), potassium phosphate monobasic (KH2PO4), potas-
siumphosphate dibasic (K2HPO4),myo-inositol, andmethanolwere pur-
chased from Sigma (Dorset, United Kingdom). High Pure RNA isolation
kits were purchased from Roche (Welwyn Garden City, United King-
dom). Penicillin-streptomycin and blasticidin were purchased from Life
Technologies (Gibco, United Kingdom). DNase-free DNase I kits were
purchased fromAmbion (Austin, TX). Anti-red fluorescent protein (anti-
RFP) antibody (5F8), anti-green fluorescent protein (anti-GFP) antibody
(3H9), and RFP-Trap or GFP-Trap agarose beads (ChromoTek) were
purchased from ChromoTek GmbH (Planegg-Martinsried, Germany).
The anti-FLAG M2 antibody (F3165) was obtained from Sigma (Dorset,
United Kingdom).
Cell culture, strains, and plasmids. All Dictyostelium axenic strains
were grown at 22°C in axenic medium containing 100 g/ml penicillin
and 100 g/ml streptomycin. Dictyostelium transformants with a dis-
rupted ino1 gene were cultured in axenic medium with 10 g/ml blastici-
din and 500 Mmyo-inositol.
Knockout constructs were created by amplifying 5= and 3= fragments
within the ino1 gene from genomic DNA of the Dictyostelium discoideum
axenic 2 (AX2) strain by PCR. The 5= and 3= PCR fragments were cloned
into the pLPBLP expression vector (31) by using BamHI-PstI and NcoI-
KpnI restriction sites, respectively. The knockout cassette was trans-
formed into wild-type (AX2) cells, and transformants were selected in
axenic medium containing blasticidin (10 g/ml). Independent clones of
transformants resistant to blasticidin were screened for homologous in-
tegration by PCR. Loss of gene transcription was confirmed by reverse
transcription-PCR. For this purpose, RNAs were extracted from the inde-
pendent clones by use of a High Pure RNA isolation kit according to the
manufacturer’s instructions. Contaminating DNAwas removed by use of
a DNase-free DNase I kit, followed by cDNA synthesis using a first-strand
cDNA synthesis kit with 1g of RNAper sample. The cDNAwas analyzed
by PCR to confirm the loss of gene transcription (using primers GCTGC
AAATCAAAAGGATCGTGCC and AAGGTGTTTTGTGGTGAACCAT
TGATG).
The Ino1-RFP overexpression construct was prepared using the full-
length ino1 (gene ID DDB_G0285505) open reading frame. The gene was
amplified from genomic DNA by use of EcoRI and BamHI flanking re-
striction sites (using primers GAGCGAATTCATGTCAGCACAAATGTT
TGAATC and TATGGATCCTAATCTTTGTTCTAATAACATG). The
PCR products were cloned into an mRFPmars expression vector (389-2)
under the control of the actin15 promoter (courtesy of Annette Müller-
Taubenberger [32, 33]). Constructs were transformed into the ino1 cell
line by electroporation and selected for neomycin resistance (10 g/ml).
Expression of Ino1-RFP was confirmed by fluorescence microscopy and
Western blot analysis using anti-RFP antibodies. ino1 gene expressionwas
confirmed by reverse transcription-PCR, using the same method as that
described for generating an ino1 knockout cell line.
Development assays and cell image acquisition. Filter assays were
used to develop Dictyostelium cells as described previously (5). Briefly,
cells grown in the presence or absence (24 h) of inositol (500 M) were
harvested during log-phase growth, and cells (1 107/ml) were plated on
a 47-mm nitrocellulose filter (Millipore, Watford, United Kingdom). Fil-
ters were incubated for 24 h at 22°C prior to imaging.
Substrate adhesion assay. ino1 or Ino1-RFP-expressing ino1 cells
grown in axenicmedium in the presence of inositol (500M)were plated
in 6-well plates, and the mediumwas replaced with axenic medium in the
absence or presence of inositol (500 M). After 24 h, the medium was
gently removed with an aspirator to dispose of the nonadherent cells.
Fresh medium was added and cells immediately resuspended and
counted, and the process was repeated for later time points.
Chemotaxis, autophagy, and cytokinesis assays. Chemotaxis assays
were carried out by using a Dunn chamber (Hawksley, Sussex, United
Kingdom) as previously described (34). Images were recorded every 15 s
over a 15-min period. Autophagy was measured in ino1 cells trans-
formed with the atg8-GFP construct (35; www.dictybase.org). Cells were
grown in axenic medium with shaking for 72 h (no-inositol conditions
had inositol removed for 24 h prior to the experiment), with 16 h of
incubation in LoFlomedium to reduce the background autofluorescence.
Cytokinesis defects weremeasured in cells cultured in shaking suspension
for 72 h, with inositol removed 24 h before the start of the assay where
indicated, and cells were fixed with 100% methanol at20°C for 15 min
prior to labeling with DAPI.
Immunoprecipitation. Initial coimmunoprecipitations were per-
formed with an ino1 cell line constitutively expressing the ino1-RFP
gene; ino1 cells constitutively expressing themRFPmars gene on its own
were used as a control (for 2 of 3 repeats), or wild-type (AX2) cell lysate
was used as a control. The presence of Ino1-RFP and RFP was confirmed
by Western blotting with anti-RFP antibody. The gel was stained with
Coomassie blue, the protein bands specific to Ino1-RFP (and absent in the
control) were evaluated bymass spectrometry, and the data were analyzed
using Scaffold3 software.
An ino1 cell line cotransformed with the ino1-RFP construct and
FLAG-gpmA, FLAG-pefB, or FLAG-Q54IX5 was used for coimmunopre-
cipitation with anti-RFP-coated beads to examine the direct interaction
between Ino1 and these proteins. Ino1-GpmA and Ino1-Q54IX5 interac-
tions were detected by Western blotting with anti-RFP and anti-FLAG
antibodies. An ino1 cell line cotransformed with the ino1-RFP construct
and either GFP-gpmA or GFP-Q54IX5 was used for coimmunoprecipita-
tion with anti-GFP-coated beads to confirm an interaction between Ino1
and these proteins; ino1 cells coexpressing mRFPmars and either GFP-
gpmA or GFP-Q54IX5 were used as a control for these experiments. The
Ino1-Q54IX5 interaction was confirmed by Western blot analysis with
anti-GFP and anti-RFP antibodies.
Cells (3  108 per experiment) were washed with phosphate buffer,
treated with 2.5 mM caffeine for 20 min with shaking, and lysed (0.5%
NP-40, 40 mM Tris-HCl, 20 mM NaCl, 5 mM EGTA, 5 mM EDTA, 10
mM dithiothreitol [DTT], 1 mM phenylmethylsulfonyl fluoride [PMSF],
and 2 protease and 2 phosphatase inhibitor cocktail [Roche]) on ice,
and the lysate was incubated with RFP-Trap or GFP-Trap agarose beads
per themanufacturer’s instructions. Briefly, the lysate was incubated with
the beads for 1 h at 4°C and then collected and washed twice (10 mM
Tris-HCl, 150 mM NaCl, 0.5 mM EDTA, 1 mM PMSF, and 2 protease
and 2 phosphatase inhibitor cocktail). The nonbound fraction was col-
lected after this step. Immunocomplexes were dissociated from the beads
by incubation at 70°C for 10 min in 4 TruPAGE LDS sample buffer
(Sigma) and then collected by centrifugation (the bound fraction) prior to
SDS-PAGE using either a Sigma TruPAGE or Bio-Rad precast gel system.
The presence of protein was detected with anti-GFP or anti-RFP antibody
or with a monoclonal anti-FLAG M2 antibody and recorded using an
Odyssey Sa infrared imaging system.
NMR spectrometry.Freeze-dried cell pelletswere resuspended in 1ml
of water-methanol (1:2) and vortexed for polar metabolite extraction.
Samples were then centrifuged at 2,400  g for 5 min, and supernatants
were kept for drying using a vacuum concentrator for 4.5 h at 45°C. Once
dried, each sample was resuspended in 80 l of phosphate buffer [in 90%
D2O and 0.05% sodium 3-(trimethylsilyl) propionate-2,2,3,3-d4 (TSP) as
a 1H nuclear magnetic resonance (NMR) reference], and 50 l of the
solution was transferred to a 1.7-mm capillary NMR tube. Spectra were
acquired at 300 K on a Bruker Avance DRX 700-MHzNMR spectrometer
(Bruker Biopsin, Rheinstetten, Germany) operating at 700.19 MHz and
equippedwith a CryoProbe from the samemanufacturer. All spectra were
acquired using a 1-dimensional nuclear Overhauser effect spectroscopy
(NOESY) pulse sequence (recycle delay-90°-t1-90°-tm-90°-acquire free
induction decay [FID]), with water suppression applied during a recycle
delay (RD) of 2 s, a mixing time (tm) of 100ms, and a 90° pulse set at 7.70
s. For each spectrum, 512 scans were accumulated over a spectral width
of 9,803.9 Hz, and all FID values were multiplied by a broadening line
function of 0.3 Hz prior to Fourier transformation. All spectra were man-
ually phased, baseline corrected, and calibrated to the TSP standard at 
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0.000 by using MestReNova software (version 10.0.1; Mestrelab Research
S.L., Spain).
Phospholipid analysis. Glycerophospholipid levels were analyzed by
mass spectroscopy as previously described (36).
RESULTS
Ino1 protein is conserved from Dictyostelium to humans. To
investigate the role of theDictyostelium Ino1 protein, we first com-
pared the Dictyostelium (accession no. Q54N49) and human (ac-
cession no. Q9NPH2-1) protein sequences (Fig. 1B and C). The
proteins share 59% sequence identity throughout their length,
have similar sizes, and show common conserved NAD binding
and catalytic domains (Fig. 1B) that are present in Ino1 proteins
from species across distant biological kingdoms (Fig. 1C), sug-
gesting a highly conserved catalytic role of Ino1 throughout evo-
lution and supporting the use of Dictyostelium to analyze Ino1
function.
An ino1 strain is an inositol auxotroph. To analyze the ef-
fects of Ino1 loss and inositol depletion on Dictyostelium cell
growth and development, we ablated 19% of the ino1 coding se-
quence, including two regions encoding highly conserved amino
acid motifs, by homologous integration of a knockout cassette
(Fig. 1B to F). The resultant ino1 cells were unable to grow in
liquid medium without inositol supplementation at concentra-
tions above 50 M (Fig. 2A), consistent with results shown previ-
ously (30). However, unlike the results of the previous study, ino-
sitol supplementation did not fully restore the ino1 growth rate
to that of the wild type, with the cells reaching a maximal level of
growth at 300 M and with higher concentrations not increasing
growth.
In Dictyostelium, starvation triggers cell differentiation and
morphogenesis to form spore-bearing fruiting bodies. We thus
investigated the effect of Ino1 loss, with and without inositol sup-
plementation, on multicellular development. Wild-type and
ino1 cells were starved on nitrocellulose filters for 24 h, and fruit-
ing bodymorphology was recorded (Fig. 2B). ino1 cells grown in
the absence of inositol for 24 h prior to nutrient deprivation were
able to aggregate but formed aberrant fruiting bodies (Fig. 2B), a
phenotype not observed for ino1 cells in an earlier report (30);
however, inositol supplementation (500 M) prior to the assay
enabled ino1 cells to produce mature fruiting bodies with wild-
type morphology.
Both growth and development phenotypes were due to a lack
of the Ino1 protein. This was shown by expression of Ino1 linked
to a C-terminal RFP tag in ino1 cells, which was localized in the
cytosol and restored wild-type growth and development (Fig. 2D
to G). Interestingly, since exogenous inositol did not fully restore
the wild-type growth rate in ino1 cells, but Ino1-RFP did, it is
likely that cells require the Ino1 protein for normal growth. ino1
cells were also unable to grow on a bacterial lawn (Fig. 2G), as
reported previously (28), even with inositol supplementation.
These results confirm a vital role for inositol in Dictyostelium
growth and development, consistent with that shown in a variety
of organisms throughout the kingdoms of life (37).
Ino1 loss triggers inositol depletion. We then quantified ino-
sitol levels in the ino1 and wild-type cells in the presence or
absence of added inositol by performing NMR spectroscopy (Fig.
3A). Wild-type cells grown in unsupplemented medium con-
tained 1.5  0.1 M inositol, and this increased significantly, to
3.4  0.1 M, following inositol supplementation (P  0.0001),
and returned to baseline following removal of inositol (Fig. 3A).
In contrast, ino1 cells grown with inositol supplementation had
an intermediate level of inositol (1.8 0.1 M) that significantly
decreased, to 0.8 0.1 M, following removal of exogenous ino-
sitol for 12 h (P  0.0013). A reduced level was maintained fol-
lowing 24 h of starvation (1.2 0.1M), and the level returned to
2.0 0.1Mfollowing reintroduction of inositol (Fig. 3A). These
data confirm that in ino1 cells, inositol was depleted following
withdrawal of exogenous inositol, and this trend is consistent with
that reported earlier (30). In addition, these data suggest that the
ino1mutant supplemented with inositol has intracellular inosi-
tol levels similar to those in wild-type cells (without supplemen-
tation) and that differences between these cell types are likely to
arise from an absence of the enzyme, enabling a range of experi-
ments to provide new insights into the distinct cell and metabolic
changes caused by inositol depletion and loss of Ino1.
Ino1 loss causes a pleiotropic phenotype. We first investi-
gated potential changes in cell movement during chemotaxis to-
ward cAMP (Fig. 3B). In these experiments, wild-type cells
showed a velocity of 9.6 1.5 m/min, with an elongated shape
(aspect) and a tendency for single-directional movement (direct-
ness) of 0.87  0.14. Loss of Ino1 plus inositol supplementation
caused a significant loss of the elongated shape, suggesting an
Ino1-dependent change. In contrast, inositol depletion in ino1
cells significantly reduced the cell speed, while the loss of shape
that was also observed for Ino1 deletion was retained, and trig-
gered increased persistence. These data suggest distinct effects
specific to Ino1 loss (loss of cell shape) and to inositol depletion
(loss of velocity).
We then examined the mechanism leading to the block in cell
growth caused by a loss of Ino1 in the absence of exogenous ino-
sitol, previously termed ‘“inositol-less death” (38). Since au-
tophagy can lead to cell death in response to cell stress or nutrient
depletion (39), we tested whether inositol depletion triggered an
autophagic response. In Dictyostelium, formation of autophago-
somes can be visualized by the incorporation of fluorescently
tagged autophagy-related protein 8 (Atg8) into autophagosomal
membranes (35). The ino1 strain grown in the absence of inosi-
tol for 24 h showed a 4-fold increase in the number of autophago-
somes per cell compared to the wild-type strain (Fig. 3C and D).
These data suggest that inositol depletion triggered an autophagic
response in ino1 cells.
We also examined the effects of Ino1 loss and inositol depletion
on substrate attachment and cytokinesis. To assess changes in cell
adhesion, the number of cells attached to plates was quantified for
up to 72 h after the removal of exogenous inositol from the ino1
mutant. In the presence of inositol (500 M), ino1 cells prolif-
erated for up to 24 h and remained adherent (Fig. 3E). Upon
removal of exogenous inositol, the ino1 cell number decreased to
88.5% of inositol-supplemented cells after 24 h and to 33.5% after
72 h. ino1 cells expressing ino1-RFP did not lose adhesion in the
absence of exogenous inositol. We then assessed cytokinesis by
comparing the numbers of nuclei per cell for the ino1 and wild-
type strains, in the presence of inositol or following inositol deple-
tion, by using theDAPI nuclear stain (Fig. 3F andG) (40). In these
experiments, ino1 cells showed a significant (P 0.001) increase
in the number of nuclei following inositol depletion compared to
that for the wild-type strain. Under inositol depletion conditions,
24.7% of the ino1 cells accumulated 3 nuclei, compared to
7.7% of the wild-type cells. This effect was rescued by growing
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ino1 cells in the presence of inositol (500 M) (9.7% of cells
accumulated 3 nuclei) or by overexpressing ino1-RFP (Fig. 3F
and G) (10% of cells accumulated3 nuclei). These data suggest
that inositol depletion leads to an increase in autophagy, a loss of
cell-substrate adhesion, and a reduction in cytokinesis but that the
loss of Ino1 per se does not trigger these responses.
Inositol depletion regulates phospholipid levels. Since inosi-
tol is a precursor to a family of inositol phospholipids (Fig. 4A and
B), we examined changes in phospholipid levels due to the loss of
Ino1 and as a result of inositol depletion. In Dictyostelium, the
following two types of phospholipids are present: diacyl phospho-
lipids, containing two acyl linkages to the glycerol backbone; and
the recently reported ether/acyl phospholipids, containing a glyc-
erol backbone linked to a fatty alcohol at position 1 (36) (Fig. 4B).
We quantified the levels of both phospholipid species in wild-type
and ino1 cells grown in the presence and absence of inositol (Fig.
4C to F). Separation of distinct phospholipid species was limited
to those of differentmolecularweights.Wefirst examined levels of
FIG 2 Ablating ino1 inDictyostelium causes inositol auxotrophy. (A)Dictyostelium cells grown in liquidmedium showed rapid growth up to stationary phase (at
168 h). Ablation of ino1 blocked cell growth in the absence of exogenous inositol, with only partial restoration of wild-type growth by the addition of either 300
Mor 500M inositol. (B) During starvation, wild-type (WT)Dictyostelium formed fruiting bodies without inositol pretreatment. Under the same conditions,
ino1 cells were unable to form fruiting bodies. Fruiting body formation in ino1 cells was restored when the cells were grown with inositol supplementation
prior to the assay. (C) Expression of ino1-RFP in Dictyostelium ino1 cells was confirmed by reverse transcription-PCR (RTPCR) with an ig7 gene control and
by Western blot analysis (WB) to show the full-length protein (with a ladder). (D to F) The full-length protein restored the growth rate (D), was present in the
cytosol (E), and restored development in the absence of exogenous inositol (F). (G) ino1 cells were unable to grow on agar plates seeded with bacteria, and
expression of ino1-RFP in these cells restored bacterial growth. For panels A and D, statistical significance was determined by two-way analysis of variance
(ANOVA) with the Bonferroni posttest. ***, P 0.001. Error bars represent standard errors of the means (SEM) for 3 experimental repeats.
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FIG 3 Inositol depletion causes a change in velocity and cell shape, an activation of autophagy, a loss in cell-substrate adhesion, and a reduction in cytokinesis
inDictyostelium ino1 cells. (A) Levels ofmyo-inositol, as analyzed by NMR spectroscopy, in wild-type and ino1 cells grown with (	; 500M) or without ()
exogenous inositol for 12 or 24 h or following inositol reintroduction (	/). Data shown are means SEM. Inositol levels were reduced in the ino1mutant
following inositol depletion for 12 and 24 h and were restored to basal levels following reintroduction for 12 h. (B) Average velocity, aspect, and persistence of
aggregation-competent ino1 cells (grown with [	] or without [] 500 M inositol for 24 h prior to imaging) or wild-type cells during chemotaxis toward
cAMP. Velocity shows the distance traveled by cells over time. Aspect refers to the roundness of cells (1  perfectly round). Directness is a ratio of the
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the phospholipid precursor phosphatidic acid (PA), which com-
prises a glycerol backbone and two fatty acid tails. Both diacyl-
linked and ether-linked PA levels decreased during early inositol
depletion in ino1 cells (Fig. 4C and D). Phosphatidylinositol
(PI), which is formed by the addition of the inositol head group to
PA, decreased following inositol depletion (in ino1 cells), with
the greatest reduction seen in diacyl-linked PI (Fig. 4C and D). A
similar effect was seen for diacyl phosphatidylinositol monophos-
phate (PIP) (Fig. 4C and D). Surprisingly, inositol depletion in-
duced a reduction in diacyl phosphatidylinositol bisphosphate
(PIP2) but not in ether/acyl PIP2 (Fig. 4C and D). For phospha-
tidylinositol trisphosphate (PIP3), only ether/acyl PIP3 was de-
tectable in ino1 cells, and the level was reduced compared to that
in wild-type cells, independent of the exogenous inositol supply
(Fig. 4D). The reintroduction of inositol for 12 h after 24 h of
starvation restored the levels of the majority of ether/acyl and
diacyl phospholipids. These data suggest that the pool of diacyl
phospholipids is more sensitive to inositol depletion than ether/
acyl species and that cellular ether/acyl PIP2 levels are maintained
under these conditions.
Since a reduction in inositol synthesis attenuates the produc-
tion of phosphoinositides and causes a transient reduction of PA,
we then monitored changes in other phospholipids during inosi-
tol depletion and rescue. No change in phosphatidylserine (PS)
was seen in wild-type cells under any condition tested; however,
diacyl phosphatidylserine levels were significantly increased in the
ino1 cells after 24 h of inositol starvation followed by inositol
resupplementation (Fig. 4E and F). Phosphatidylcholine levels did
not change significantly in wild-type or ino1 cells under any con-
dition (Fig. 4E and F), while the ether/acyl phosphatidylethano-
lamine level was decreased in ino1 cells after 12 h of inositol
starvation (Fig. 4F).
Ino1 loss causes a shift to catabolic metabolism. We next in-
vestigated themetabolic consequences of both the loss of Ino1 and
inositol depletion by using wild-type and ino1 cells grown in the
presence and absence of inositol (Fig. 5). Both ablation of ino1 and
inositol treatment induced specific metabolic changes. Principal
component (PC) analysis of metabolic profiles suggested that the
greatest metabolic change was observed between the wild-type
and ino1 cells independently of exogenous inositol provision
(Fig. 5A and B), where ino1 ablation accounted for 53% of the
total variance, as observed in PC1. The mutation resulted in in-
creases in amino acids and compounds related to amino acid
breakdown (alanine, aspartate, isoleucine, lysine, methionine,
GABA, and putrescine), in energy-related metabolites (fumarate
and lactate), in phosphorylated adenosine derivatives (5=AMP,
3=AMP, ATP, and cAMP), and in sn-glycero-3-phosphocholine
(GPC), a potent osmolyte (Fig. 5B). In contrast, inositol treatment
accounted for only 12% of the variance between the metabolic
profiles of wild-type and ino1 cells, as observed in PC2 (Fig. 5A
and C). In ino1 cells, inositol treatment resulted in increased
amino acid levels (leucine, methionine, and tyrosine). These data
suggest a dominant role for the presence of the Ino1 protein
(rather than inositol levels) in metabolic regulation (Fig. 5).
The absence of Ino1 caused a major shift in metabolic profile,
and we therefore specifically examined changes caused by Ino1
loss (Fig. 6A and B). This analysis showed changes in many of the
metabolic products found in the initial PC analysis. In contrast to
a loss of Ino1, inositol depletion caused limited changes to meta-
bolic profiles. Here we specifically compared ino1 cells grown in
the presence or absence of inositol (12- and 24-h treatments were
combined because they resulted in similar metabolic changes and
inositol levels) (Fig. 6C and D) to show that inositol supplemen-
tation led to an increase of inositol and lipids, consistent with the
phosphoinositide analysis (Fig. 4). Interestingly, reintroduction
of inositol for 12 h after 24 h of inositol depletion changed the
metabolic profile of ino1 cells (Fig. 6E and F).
Supervised analysis was then used to specifically evaluate the
impact of Ino1 loss on cell metabolism (Fig. 6 and 7). This ap-
proach suggested that a loss of Ino1was associatedwith significant
increases in some amino acids (alanine, aspartate, glycine, GABA,
isoleucine, lysine, and methionine) and in metabolites associated
with regulation of the cell cycle andDNAmetabolism (guanosine,
ATP, deoxy-ADP, 5=AMP, 3=AMP, UTP, and 
-alanine, a bio-
marker of the degradation of pyrimidines [41]). Putrescine was
also significantly increased, consistentwith a reduction in cell pro-
liferation, as previously demonstrated for Dictyostelium (42). An
increase in lactate was also observed, which suggests an increase in
the (NADH	H	)/NAD	 ratio that stimulates the activity of the
lactate dehydrogenase. An increase in (NADH	H	)/NAD	 ra-
tio would simultaneously inhibit the citrate synthase and slow
down the Krebs cycle, resulting in an accumulation of some inter-
mediates. This is consistent with the accumulation of acetate, de-
rived from the spontaneous hydrolysis of oxaloacetate, and of fu-
marate and succinate, two other intermediates of the Krebs cycle.
Finally, the GPC level was greatly increased, suggesting that the
lack of Ino1 was compensated for by the production of a strong
osmolyte. The increased (NADH 	 H	)/NAD	 ratio is a signa-
ture of catabolic reactions. Together, these data suggest that the
loss of Ino1 shifts cells into a catabolic state and further support
the autophagic phenotype of ino1 mutants, even when supple-
mented with inositol.
Supervised analysis was also used to evaluate the impact of
inositol depletion on individual metabolites (Fig. 6 and 7). This
approach suggested that inositol depletion resulted in changes in
some amino acids (increases in alanine, GABA, glycine, and valine
and a decrease in phenylalanine), increases in lactate, fumarate,
and succinate, and decreases in 3=AMP, guanosine, and glycogen.
No effect on the metabolic profile was shown to be due to the
selection antibiotic (blasticidin) for the ino1 cells (orthogonal
distance traveled by a cell to the total direct distance, where 1 represents a straight line. (C and D) Autophagosomes were visualized in wild-type and ino1 cells
expressing Atg8-GFP (C) and quantified in the absence of inositol (24 h) (control) or presence of inositol (D). (E) Cell adhesion wasmonitored in wild-type and
ino1 cells and in ino1 cells expressing ino1-RFP in the presence (500 M) or absence of inositol for at least 24 h. (F and G) Cytokinesis was examined in
wild-type and ino1 cells and in ino1 cells expressing ino1-RFP by using the DAPI nuclear stain to label cell nuclei (F), and the number of nuclei per cell was
quantified (G). For panels A, B, D, and E, statistical significance was determined by the unpaired two-tailed t test, with each condition compared separately to
wild-type cells ( inositol) (A, B, and D) and ino1 cells (	 inositol) (D). For panels E and G, statistical significance was determined by 2-way ANOVAwith the
Bonferroni posttest. *, P 0.05; **, P 0.01; ***, P 0.001. Error bars represent SEM. For panel A, there were 4 experimental repeats. For panel B,20 cells
were analyzed per condition in 3 experimental repeats. For panel D, 117 cells were analyzed per condition in 3 experimental repeats. For panel E, there were 3
experimental repeats. For panel G, 386 cells were analyzed per condition in 3 experimental repeats.
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FIG 4 Inositol depletion affects phosphoinositide levels in Dictyostelium. (A) Metabolic pathway depicting phospholipid production from phosphatidic acid
(PA) as an example. (B) Structure of phosphoinositol, showing diacyl or ether/acyl fatty acid linkages to a glycerol backbone and an inositol head group. (C to
F) To monitor phospholipids in wild-type and ino1mutant cells, cells were grown in the presence of inositol (500 M;	), with inositol followed by inositol
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projection to latent structure [O-PLS] model parameters: R2Y
0.18 and Q2Y 0). Although we observed that the mutants were
already in a catabolic state, the addition of inositol tended tomod-
erate this metabolic phenotype, since indicators of anabolism
(glycogen and lipids) were higher in cells supplemented with ino-
sitol, while those not supplemented were associated with markers
of catabolism (i.e., lactate and succinate). However, the absence of
Ino1 rather than inositol depletion triggered broader metabolic
changes.
Mutation of an Ino1 catalytic residue reduces growth inde-
pendently of exogenous inositol. To investigate a role for Ino1
that is independent of catalytic activity, we expressed a mutated
Ino1 protein lacking a key catalytic aspartic acid (D342A) that is
conserved throughout the tree of life (37).Wild-type cells express-
ing this construct showed strongly reduced growth in either the
presence or absence of inositol (500 M) (Fig. 8A), suggesting a
dominant negative effect of the protein. ino1 cells expressing this
construct retained the inositol-auxotrophic phenotype, confirm-
ing a lack of catalytic activity of themutated protein, but addition-
ally showed strongly reduced growth in the presence of inositol
(500 M).
Ino1 binds a possible macromolecular complex linker pro-
tein. To investigate a mechanism for Ino1 in regulating cell func-
tion independently of catalytic activity, Ino1 binding partners
were isolated by coimmunoprecipitation. Ino1-RFP was ex-
pressed in ino1 cells, bound to anti-RFP antibody-coated agarose
beads, and purified by coimmunoprecipitation, followed by SDS-
PAGE separation and mass spectrometry analysis (Fig. 8B). This
approach identified 104 potential binding partners from three in-
dependent experiments, and these were divided into six major
groups, namely, actin-related, immunity- and stress-related, me-
tabolism, nucleic acid-related (translation, transcription, regula-
tion of gene expression, and DNA recombination), protein catab-
olism, and modification and transport proteins, as well as others,
encompassing signal transduction, ATP hydrolysis, and proton
transport (including V-type proton ATPase catalytic subunits A
and B) (see the supplemental material). We extended our analysis
for three potential Ino1 binding proteins: GpmA, a phosphoglyc-
withdrawal (for 12 or 24 h; 	/), or with inositol added after a 24-h depletion period (500 M for 12 h; 	//	). The controls were cells without inositol
supplementation. The levels of ether/acyl (C34:1 ea) or diacyl (C36:3 aa) phospholipids are shown as percentages relative to phospholipid levels present in the
wild-type strain grown in the absence of inositol. Inositol depletion reduced the levels of diacyl PI, PIP, and PIP2 phosphoinositides; the level of diacyl PIP3 was
undetectable, and the levels of ether/acyl PIP andPIP3were reduced. Statistical analysis was carried out by comparing two groups at a time: wild-type (	 inositol)
versus ino1 (	 inositol) cells, wild-type (	 inositol) versus ino1 (	/ inositol 12 h) cells, wild-type (	 inositol) versus ino1 (	/ inositol 24 h) cells, and
wild-type (	 inositol) versus ino1 (	/ 24 h/	 12 h inositol) cells. Comparisons were done by the unpaired two-tailed t test to illustrate the significance of
changes due to the loss of the Ino1 protein. *, P 0.05; **, P 0.01; ***, P 0.001. Error bars represent SEM for 3 experimental repeats.
FIG 5 Comparison ofmetabolic profiles ofDictyostelium following Ino1 loss and inositol depletion. Tomonitormetabolic profiles in thewild type and the ino1
mutant, cells were grown in the presence of inositol (500 M;	), with inositol followed by inositol withdrawal (12 or 24 h;	/), or with inositol added after
a 24-h depletion period (500M for 12 h;	//	). The controls were cells without inositol supplementation. (A) Distribution of metabolic variations between
cell type and myo-inositol exposure were assessed by principal component analysis (PCA) of data generated from the 1H-NMR spectra of the Dictyostelium
metabolic fingerprints. The main source of variation (53%) was driven by the mutation, while inositol depletion accounted for approximately 12% of the
metabolic variation in this data set. (B) Loading plot associated with PC1 (red peaks pointing upwards are positively associated with PC1, while those pointing
downwards are negatively associated with PC1). (C) Loading plot associated with PC2. A total of 5 experimental repeats were performed.
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FIG 6 Metabolic profile analysis of the ino1mutant. Cells were grown in the presence of inositol (500 M;	), with inositol followed by inositol withdrawal
(12 or 24 h; 	/), or with inositol added after a 24-h depletion period (500 M for 12 h; 	//	). (A and B) Metabolic changes induced by ino1 ablation.
Orthogonal projection to latent structure discriminant analysis (O-PLS DA) was used to determine the specific impact of the mutation on cell metabolism. (A)
Plot of the scores against the cross-validated scores generated byO-PLSDA (R2Y 0.89,Q2Y 0.88, andP value for 500 randompermutations 0.002) by using
the 1H-NMR spectra of theDictyosteliumwild-type and ino1 cells (except for the	/ 24 h/	 12 h inositol exposure) as a matrix of independent variables and
using mutation as a predictor. (B) Loading plot of the O-PLS DAmodel (peaks in red indicate increased metabolite levels in response to the mutation). (C and
D) Effect of inositol treatment on the metabolism of the ino1mutant. (C) Plot of the scores against the cross-validated scores generated by O-PLS DA (R2Y
0.67,Q2Y 0.51, and P value for 500 permutations 0.002) by using the 1H-NMR spectra of the ino1 cells (12 h and24 h inositol versus	 inositol) as a
matrix of independent variables and using depletion of myo-inositol as a predictor. (D) Loading plot of the O-PLS DA model (peaks in red indicate increased
metabolite levels in response to the presence of inositol). (E andF)Reintroduction ofmyo-inositol postdeprivation induces ametabolic shift. (E) Plot of the scores
against the cross-validated scores generated by O-PLS DA (R2Y 0.90,Q2Y 0.86, and P value for 500 permutations 0.002) by using the 1H-NMR spectra of
the ino1 cells (12 h and24 h inositol versus	//	 inositol) as a matrix of independent variables and usingmyo-inositol reintroduction as a predictor. (F)
Loading plot of the O-PLS DA model (peaks in red indicate increased metabolite levels in response to the depletion ofmyo-inositol). A total of 4 experimental
repeats were performed.
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FIG 7 Levels of metabolites in wild-type and ino1 cells grown under various inositol conditions. Metabolite levels measured by NMR spectroscopy were
quantified using MATLAB and plotted to illustrate changes observed in wild-type and ino1 cells for amino acids (A), cell cycle- and DNA-related metabolites
(B), and other metabolites (C). The controls were cells without inositol supplementation. Statistical analysis was carried out for wild-type (AX2) (	 inositol)
versus ino1 (	 inositol) cells by the unpaired two-tailed t test to illustrate the significance of changes due to the loss of the Ino1 protein. *, P 0.05; **, P 0.01;
***, P 0.001. A separate unpaired two-tailed t test analysis was used to compare ino1 (	 inositol) versus ino1 ( inositol 12 h) cells and ino1 (	 inositol)
versus ino1 ( inositol 24 h) cells.	, P 0.05;		, P 0.01;			, P 0.001. Error bars represent SEM for 5 experimental repeats per sample per condition.
a.u., arbitrary units.
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erate mutase that catalyzes the production of 2,3-bisphospho-D-
glycerate (2,3BPG), which was found to accumulate in ino1 cells
starved of inositol (30); PefB, a penta-EF hand domain-contain-
ing protein linked to neurodegenerative and lysosomal diseases
(43, 44); andQ54IX5, an uncharacterized protein with three Sel1-
like repeats which was present in all three independent immuno-
precipitation experiments (Fig. 8C and D). These proteins tagged
with a FLAG epitopewere coexpressed in cells with Ino1-RFP, and
Ino1-RFP was immunoprecipitated from cell lysates by use of an
RFP antibody linked to agarose beads. The bound protein frac-
tions were then analyzed for the presence of each FLAG-tagged
protein, which demonstrated that GpmA-FLAG bound Ino1-RFP
weakly, whereas Q54IX5-FLAG bound strongly to Ino1-RFP (Fig.
8C). The Q541X5-Ino1 interaction was confirmed by using the
reverse approach,whereQ54IX5-GFPwas coexpressedwith Ino1-
RFP and immunoprecipitated with a GFP antibody linked to aga-
rose beads; coimmunoprecipitated Ino1-RFP was detected by
Western blotting with an RFP antibody (Fig. 8D). These ap-
proaches confirmed that Q54IX5 binds strongly to Ino1.
DISCUSSION
Inositol and inositol-containing compounds are vital cellular
components, and a range of studies have identified pleiotropic
effects of inositol depletion on cell function but have not consid-
FIG 8 Noncatalytic role for Ino1 in Dictyostelium. (A) An Ino1-RFP protein with an aspartic acid-to-alanine substitution (ino1D342A) in a highly conserved
region of a catalytic domain was overexpressed in wild-type and ino1 cells. In the ino1 cells, the mutated protein was unable to rescue the ino1 inositol
auxotrophy, consistent with a catalytically inactive protein. In the wild-type cells, expression of the mutant protein significantly decreased growth, while the
addition of exogenous inositol partially rescued this phenotype. Statistical analysis was carried out for each individual condition compared to wild-type (AX2)
cells by the unpaired two-tailed t test. *, P  0.05; ***, P  0.001. Error bars represent SEM for 3 experimental repeats. (B) Coimmunoprecipitation of the
Ino1-RFP protein (or an RFP-only control) expressed in ino1 cells by use of anti-RFP-coated beads. Both bound (B) and nonbound (NB) fractions are shown.
Proteins in SDS-PAGE gels were visualized following Coomassie staining (left) and analyzed by Western blotting with an anti-RFP antibody (right). Bands
specific to Ino1-RFP (and absent from the RFP control) were analyzed by mass spectrometry to identify potential Ino1 binding partners. (C) FLAG-tagged
potential interacting proteins GpmA, PefB, and Q541X5 were investigated by immunoprecipitation using Ino1-RFP and anti-RFP-coated beads, followed by
Western blottingwith anti-RFP and anti-FLAGantibodies. (D)An Ino1-Q54IX5 interactionwas confirmedby immunoprecipitation of theGFP-Q54IX5protein
with anti-GFP-coated beads in the presence of Ino1-RFP (or RFP only) and Western blot analysis with anti-RFP and anti-GFP antibodies.
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ered complications due to altered levels of the biosynthetic en-
zyme Ino1. To distinguish between the effects of inositol depletion
and a loss of Ino1 on cell function andmetabolism, we ablated the
inositol biosynthetic enzyme Ino1 inDictyostelium and compared
wild-type cells and cells without Ino1 in the presence and absence
of inositol. Loss of Ino1 produced an inositol-auxotrophic pheno-
type during growth and blocked development, confirming the re-
sults of an earlier Dictyostelium study (30) and results for diverse
organisms, ranging from Saccharomyces cerevisiae (45) to mice
(46), demonstrating the essential conserved role of inositol in cel-
lular function. We showed that the myo-inositol levels decreased
by 36 to 56% in the ino1 mutant (depending upon starvation
time) and returned to predepletion levels following inositol re-
plenishment. This inositol depletion response is consistent with
an obligate role for inositol production catalyzed by Ino1. We
showed that inositol depletion resulting from ino1 ablation blocks
development, reduces cell velocity, upregulates autophagy, and
inhibits cytokinesis, consistent with a range of studies in other
systems (19, 30, 47–49) and confirming the validity of this model
for studying Ino1 function. All of these phenotypes, except growth
and cell shape, are rescued by provision of exogenous inositol and
are thus likely to be due to inositol depletion rather than the loss of
Ino1.
Dysregulation of inositol levels has been reported in a wide
range of biomedical and clinical studies, both relating to disease
conditions and as a result of medicinal treatment, although few
studies have addressed specific changes in Ino1 protein levels. A
range of structurally independent bipolar disorder drugs, includ-
ing carbamazepine, valproate, and lithium, act via an inositol de-
pletion mechanism (5) and induce autophagy in vitro and in vivo
(50, 51) to promote survival by recycling cellular components (47,
49). Altered inositol levels have also been demonstrated in patient
studies of bipolar disorder (52), major depressive disorder (53),
and schizophrenia (54). For these reasons, modulating inositol
levels was proposed as a therapy for the treatment of bipolar dis-
order (55), depression, and panic disorders (56). In addition, Ino1
activity and protein levels are elevated in postmortem brains of
Alzheimer’s patients (57), although studies showed pathologically
lowered inositol levels and mitochondrial dysfunction in mouse
models of Alzheimer’s disease (8) that could be linked to au-
tophagy (58). However, no distinction was made in these studies
between altered inositol levels and altered Ino1 levels. In the pres-
ent study, we separated the effects caused by altered Ino1 levels
and inositol depletion to provide a unique approach to monitor
cellular and metabolic changes related to inositol levels.
Since phosphoinositide production is the first step of inositol
incorporation into cell signaling, we examined the effects of a loss
of Ino1 and inositol depletion on this family of chemicals, analyz-
ing both diacyl-linked and ether/acyl-linked compounds inde-
pendently (36). Inositol depletion induced rapid reductions in
both species of PI and PIP and strongly reduced diacyl PIP2 levels,
but it had little effect on ether/acyl PIP2. Surprisingly, PIP3 was
greatly reduced in the ino1 mutant under all conditions, inde-
pendent of exogenous inositol. Overall, the greater reduction in
diacyl phosphoinositides, comprising less than 5% of the inositol
phospholipids (36), may be due to the preferential metabolism of
these species over that of the ether/acyl derivatives as precursors of
inositol phosphates. Alternatively, these compounds may provide
a more labile signaling component, giving rise to more rapid me-
tabolism than that of ether-derived compounds, and further re-
search could investigate these alternatives. Nevertheless, these
data show a critical effect of inositol depletion in regulating phos-
phoinositides.
These results also suggest an important role of inositol deple-
tion, through regulating diacyl PIP2 in vesicle formation and
transport (59) and in membrane trafficking at the neuronal syn-
apse (60). In Dictyostelium, ablation of the PIP2 biosynthetic en-
zyme PIP5 kinase (PikI) led to a 90% reduction in PIP2 levels and
to disoriented cell movement (61). The pivotal role of PIP2 in
these processes suggests a requirement for cells to maintain the
level of this essential molecule during inositol starvation. Cytoki-
nesis is also critically dependent upon an increase in PIP2 levels
(48), and a 65% reduction in diacyl PIP2 levels following 24 h of
inositol depletion is consistent with a block in cytokinesis giving
rise to the multinucleate phenotype of ino1 cells. In a similar
manner, PIP2 is involved in substrate attachment by regulating
actin polymerization and depolymerization (48), which may re-
sult in reduced cell-substrate adhesion. Overall, the data suggest
that inositol depletion has a fundamental and rapid effect on
phosphoinositide regulation that is likely to result inwide-ranging
changes in cellular function and cell health.
Interestingly, Ino1 may play a role in regulating PIP3 levels
regardless of the inositol level, since the ino1 mutant grown in
inositol-supplementedmedium showed reduced PIP3 levels, even
though intracellularmyo-inositol levels were comparable to those
of wild-type cells. Previous studies inDictyostelium demonstrated
that a complete block of PIP3 production by deletion of all five
phosphoinositide 3-kinase enzymes resulted in poor growth and
developmental defects (62). Combined, these findings suggest
that loss of the Ino1 protein leads to a loss of PIP3 production,
resulting in poor cell growth.
We also examinedmetabolic changes caused by loss of the Ino1
protein and during inositol depletion. Surprisingly, the greatest
metabolic change observed here was due to an absence of Ino1,
which gave rise to elevated amino acids, energy-related compo-
nents, DNA regulation, and osmolytes. This metabolic shift was
not due to altered inositol levels per se, since cellular inositol levels
were consistent between the mutant and wild-type cells during
inositol supplementation, but rather to an absence of the Ino1
protein. These changes are likely to have a major effect on cellular
function and suggest an important noncatalytic role for the pro-
tein in metabolic regulation, shifting the metabolism toward an
autophagic response, with increased levels of putrescine, amino
acids, and nucleotide derivatives (63). In contrast, inositol deple-
tion caused general changes in lipids and variable changes in a few
amino acids. This suggests that inositol depletion has little meta-
bolic effect over the short time scale examined in this study.
Since inositol supplementation did not fully restore ino1
growth, we expressed the mutant protein Ino1-D342A in these
cells and assessed growth. Mutation of this amino acid is likely to
disrupt catalytic activity as it is conserved in all known Ino1 pro-
teins. Expression of Ino1-D342A did not rescue the inositol
auxotrophy resulting from Ino1 loss, and thus it does not cat-
alyze inositol biosynthesis. In contrast, expression of the protein
reduced growth of all strains, independently of exogenous inositol
provision. Further studies will be necessary to determine if this
response is due to depletion of the Ino1 substrate, inactivation of
a potential Ino1 multimeric complex, or other mechanisms.
To identify new roles for Ino1 in the regulation of cellular
function, we isolated a number of potential Ino1 binding partners.
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These included proteins related to cytoskeletal organization, mi-
tochondrial function, DNA and protein regulation, and metabo-
lism, including fatty acid metabolism, glycolysis, and purine me-
tabolism, as well as the vacuolar ATPase, consistent with those
identified in S. cerevisiae (64–66) and in humans (67). From the
list of potential binding partners, we independently confirmed
Ino1-GpmA binding; GpmA catalyzes the production of 2,3BPG
from 2- or 3-phosphoglycerate. Importantly, 2,3BPG potently in-
hibits the dephosphorylation of InsP3 and InsP2 (68), relating to
the effect of lithium on the dephosphorylation of IP1 (9), and is
elevated following ino1 loss in Dictyostelium (30). The binding of
Ino1-GpmA thus provides a potentially crucial link between loss
of Ino1 and a mechanism of inositol depletion similar to that for
lithium. We also confirmed strong Ino1-Q54IX5 binding; the
Q54IX5 protein contains a tetratricopeptide repeat (TPR) that
mediates protein-protein interactions, often during the assembly
of multiprotein complexes (69). Although the function of an
Ino1-Q54IX5 interaction remains to be examined, the potential
human orthologue of Q54IX5 is the SEL1L protein, which is in-
volved in themovement ofmisfolded proteins from the endoplas-
mic reticulum to the cytosol and in protein ubiquitination (70),
and thus dysregulation of this protein in the ino1 mutant may
have far-reaching effects on cell function.
Since we showed that the absence of Ino1 and inositol deple-
tion have differentmolecular andmetabolic effects, we questioned
whether these effects are interrelated. Inositol depletion has been
shown to activate ino1 expression in a wide range of models (71,
72), including Dictyostelium (5) and mice (73); this effect is likely
to elevate Ino1 levels. Many studies have relied on using inositol-
depleting drugs prescribed as bipolar disorder treatments, which
act through multiple targets (74–77), and hence these studies are
likely to be complicated by secondary effects. In contrast, our
study did not utilize drug treatments, and our results suggest that
short-term inositol depletion does not cause large metabolic
changes in Dictyostelium, enabling a subsequent increase in ino1
transcription to reverse this deficit (5). This responsive regulation
would protect cells against a transient reduction in inositol levels
without triggering large metabolic changes, with a dysregulation
of this responsive mode resulting from a reduction of Ino1 levels
causing wide-ranging metabolic effects.
To sum up, our studies show that a loss of the crucial inositol
biosynthetic enzyme Ino1 and inositol depletion cause discrete
cellular, molecular, and metabolic effects. Although inositol de-
pletion alters cell physiology, triggering an autophagic response,
loss of substrate adhesion, reduction in cell division, and rapid
reductions in a range of phospholipids, it does not trigger a large
change in metabolic profile. In contrast, the Ino1 protein itself
plays important roles in cell growth and shape and in metabolic
regulation, regardless of inositol level, including binding to a
linker protein, Q54IX5, suggesting further roles of this protein.
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